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 There approximately 5.1 million Americans who may have Alzheimer’s disease (AD). 
This number is expected to increase with the increase in the aging population. Theories based on 
genetic and neuropathological findings suggest genetic mutations are responsible for AD. There 
are 7 stages of AD.  The stages of disease are a reference on how the disease may progress, but 
not all stages are experienced by all persons with AD.  AD can only be diagnosed by 
histopathologic examination of the brain there for clinical criteria are utilized for diagnosis. 
Clinical criteria include diagnostic tests such as laboratory and imaging studies, 
neuropsychological testing, mental status exam, and neurologic exam.  The majority of persons 
with AD exhibit behavioral symptoms. Behavioral symptoms may include disruptive 
vocalization (screaming), restlessness, repetitive questions, wandering, pacing, and physical 
aggression toward self or others.  Treatment of behavioral symptoms is challenging and a wide 
range of interventions are utilized by caregivers and health care professionals. Chemical and 
physical restraint utilization for behavioral symptoms can lead to a higher risk for falls. Family 
caregivers of AD patients have a high incidence of depression as consequence of caring for a 
person with dementia.  Therapeutic touch is a non-pharmacologic intervention that has been 
minimally utilized for the treatment of behaviors seen in patients with AD.  It has been found 
through research to decrease stress and anxiety, and to improve quality of life and emotional, 
physical, and spiritual well-being. Evidence has shown therapeutic touch does not cause patients 
any harm.  An intensive review of the literature and studies on the use of therapeutic touch as an 
intervention to treat behavioral symptoms of AD indicates that it is appropriate for primary care 
givers to consider therapeutic touch therapy to treat behaviors of patients with AD.  
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Effect of Therapeutic Touch in Treating Agitation of Persons with Alzheimer’s Disease 
 Experts estimate there are 5.1 million Americans who may have Alzheimer’s disease 
(AD) (National Institutes of Health (NIH), 2008).  AD is the most common forms of dementia in 
the older population.  Agitated behaviors, including hitting, screaming, pacing, repetitive 
sentences or questions, throwing, hoarding, sexual advances, restlessness, and hurting self or 
others occurs in approximately 90% of persons with advanced dementia (Wang & Hermann, 
2006).  Agitation affects the quality of life of Alzheimer’s patients, their families, and their 
caregivers.  Behaviors increase the risk of falls, social isolation, and the use of chemical and 
physical restraints (Hawranik, Johnston, & Deatrich, 2008).  Experienced caregivers have 
reported an extreme caregiver burden of caring for patients with AD in relation to agitated 
behaviors (Parahoo, Whall, Colling, & Nusbaum, 2005).  Burden develops as a result of the 
chronic emotional and physical stress of caring for a person with AD (Papastravou, Kalokerinou, 
Papcostas, Tsangari, & Sourtzi, P, 2007).  The caregiver burden can lead to depression and a 
decline in physical health, leading to a poor quality of life for the caregiver.  Several 
interventions are applied in hopes of calming the person and minimizing the behavior (Woods, 
Craven, & Whitney, 2005).  Pharmacotherapy with anti-anxiolytics and/or antipsychotics, pet 
therapy, recreational activities, and music are some examples of interventions utilized to treat 
agitated behaviors. Touch therapies have existed for centuries throughout the world, but have 
recently been used as an intervention to help decrease and treat agitated behaviors in persons 
with AD (Wang & Hermann, 2006).  Therapeutic touch is an intervention in which energy 
imbalances are identified and corrected by a therapeutic touch practitioner (Hawranik, Johnston, 
& Deatrich, 2008). The aim of this paper is to present the effectiveness of therapeutic touch as an 
intervention to decrease agitated behaviors in persons with AD. 




 Alzheimer’s Disease  
Definition 
 AD is an irreversible disorder of the brain in which memory is slowly destroyed and 
thinking skills deteriorate usually over several years (NIH, 2008).  In most cases, symptoms first 
occur after age 60. 
Epidemiology 
 There is a significant increase in the aging population worldwide.  In the year 2000 there 
were 420 million people ages 65 and older in the world (Qui, Kivipelto, & Strauss, 2009). This 
number is expected to increase to nearly 1 billion by the year 2030.  In the United States (U.S.) 
alone it was estimated that 13% of the population were 65 years of age or older in the year 2010 
(Vincent & Velkoff, 2010). “By 2030, there will be 71 million American older adults (ages 65 
and older) accounting for roughly 20% of the U.S. population” (Center for Disease Control and 
Prevention and The Merck Company Foundation, 2007, p. III).  AD is associated with increasing 
age, therefore it is estimated the population with AD will increase with the aging population (Qui, 
Kivipelto, & Strauss, 2009).  According to the Alzheimer’s Association (2011), the estimated 
annual incidence of AD in the United States increases with age “from approximately 53 new 
cases per 1,000 people aged 65-74, to 170 new cases per 1,000 people aged 75-84, to 231 new 
cases per 1,000 people over the age of 85” (p. 14).  There are more than 25 million people 
worldwide with dementia, mostly caused by AD. Approximately 60-80% of dementia cases are 
caused by AD (Alzheimer’s Association, 2011). The second most common cause of dementia is 
vascular dementia.  This type is caused by decreased blood flow to areas of the brain as a result 
of blocked arteries or small strokes. There are several less common types of dementia including 




mixed dementia, dementia with Lewy bodies, Parkinson’s dementia, frontotemporal dementia, 
Creutzfeldt-Jakob disease, and normal pressure hydrocephalus. There is an estimate of around 5 
million new cases of dementia each year. Approximately two-thirds of Americans with AD are 
female. Women have a longer average life span than men, accounting for the higher prevalence 
of AD in women.  Age specific studies have shown the incidence of AD or any dementia is not 
significantly different between males and females.   
Impacts of Alzheimer’s Disease 
 AD shortens life expectancy and causes physical disabilities, institutionalization, 
therefore decreasing the person’s quality of life (Qui, Kivipelto, & Strauss, 2009). “AD is the 
sixth leading cause of death across all ages in the U.S.” (Alzheimer’s Association, 2011, p. 20). 
Deaths attributed to AD increased by 66% from the year 2000 to 2008. “Regardless of the cause 
of death, 61% of people with AD at age 70 are expected to die before age 80 compared to 30% 
of people at age 70 without AD” (Alzheimer’s Association, 2011, p. 21). The median survival 
time with a diagnosis of AD is 3-6 years (Qui, Kivipelto, & Strauss, 2009). It has been estimated 
that 43% of individuals with AD need high level of care, such as nursing homes. Due the 
cognitive decline in people with AD it is expected they will need supportive caregivers and 
higher levels of care (Alzheimer’s Association, 2011). As the person advances across the stages 
of AD the assistance needed increases.  As the disease progresses people with AD need 
assistance with activities of daily living, such as grocery shopping, managing finances, taking 
medications correctly, bathing, and dressing (Alzheimer’s Association, 2011). Caregivers of 
people with AD provide assistance to find and use medical services. Caregivers are responsible 
to manage safety issues and behavioral symptoms of the disease, such as agitation or wandering.  
AD patients with co-morbidities, such as coronary artery disease or diabetes, are more likely to 




be hospitalized than people with the same medical condition but do not have an AD diagnosis or 
other dementia.  In addition, patients with AD have longer hospital stays. In 2005 it was 
estimated that the societal costs of dementia was more than $315 billion in the United States (Qui, 
Kivipelto, & Strauss, 2009).   
Pathophysiology 
AD was named after Dr. Alois Alzheimer, who in 1906 discovered abnormal clumps and 
bundles of fibers in a female patient who had died of an illness with symptoms of memory loss 
and unpredictable behavior (NIH, 2008). The abnormal clumps are now known as amyloid 
plaques and the bundles of fibers are now called neurofibrillary tangles.  
The complete pathophysiology of AD is not fully understood, but there are theories based 
on genetic and neuropathological findings (Chouliaras et al, 2010). There are two broad 
categories of AD, early onset and late onset. According to Chouliaras et al (2010), studies 
suggest mutations of amyloid-precursor protein genes and presenilin 1 and 2 genes in connection 
with familial early onset AD.  The majority of AD cases are late onset and have been linked to 
the variation of the apolipoprotien E4 genotype.  The neuropathological hallmarks of AD include 
the loss of neurons and synapses resulting in neuritic plaques composed of beta-amyloid fibrils 
and neurofibrillary tangles composed of tau protein. The plaques accumulate due to the 
endoproteolysis of the amyloid-precursor protein. The neurofibrillary tangles are formed from 
the hyperphosphorylation of the tau protein. Synaptic and neuronal dysfunction, disruptive 
synaptic and neuronal integrity, and synaptic and neuronal loss in the brain occur as a result of 
the amyloid plaques and neurofibrillary tangles leading to impairments of cognitive functioning.  
Stages of the Alzheimer’s Disease 




 Patterns of the progression of symptoms of AD are classified into stages (Alzheimer’s 
Association, 2007). Nerve cell damage begins with the cells involved with memory and learning, 
and then gradually effects cells controlling aspects of thinking, judgment, and behavior. 
Eventually the cell damage affects movement and coordination. There are seven stages of AD 
based on the framework of Barry Reisber, M.D. The staging system is a reference on how the 
disease may progress, but not all stages are experienced by all persons with AD.  Symptom 
presentation may vary significantly from person to person. The stages of AD are often referred to 
by health professionals with widely used concepts of mild, moderate, moderately severe, and 
severe AD along with early-stage, mid-stage, and late-stage categories. 
The Alzheimer’s association (2007) provides the following description of the various stages of 
AD: 
- Stage one is identified as the stage with no cognitive impairment. There are no memory 
problems experienced and no symptoms of AD are evident to a health care professional 
during a medical interview because the person has normal function. Therefore, a 
diagnosis during this stage is not possible. 
- Stage two is identified as a mild decline in cognitive functioning. The person may forget 
familiar words, the location of keys, names, or other everyday objects and might be 
aware of these memory lapses. These problems are not evident during a medical exam or 
apparent to friends or family. 
- Stage three is associated with mild cognitive decline. This stage is identified as part of the 
early-stage AD category. During this stage, family or friends may notice deficiencies.  
There may be memory and concentration problems measurable with clinical testing 
during a medical exam and interview. Common symptoms during this stage include 




difficulties with word finding, naming of family or close associates, decreased ability to 
remember names after introductions to new people, performance issues in social 
environments noticeable to others, decreased ability to retain reading material, losing 
objects, and decline in the ability to organize or plan. 
- Stage four is when moderate cognitive decline occurs. This stage is considered part of the 
mild or early-stage AD categories. A medical interview can identify cognitive 
deficiencies. The symptoms include, decreased knowledge of recent events, impaired 
ability to perform challenging mental arithmetic such as counting backward from 100 by 
7’s, decreased ability to perform complex tasks, such as paying bills, reduced memory of 
personal history, and withdrawal from socially and mentally challenging situations. 
- Stage five is recognized as the stage with moderately severe cognitive decline and is 
considered in the moderate or mid-stage AD categories. Major gaps in memory and 
cognitive deficits emerge resulting in a need for assistance with daily activities. During a 
medical interview the client may be unable to recall important details, such as their 
address or phone number. At this stage of AD persons may exhibit confusion in 
orientation to person, place, and time. There may be trouble with simple mental 
arithmetic, such as counting back from 20 by 2’s.  Help is needed to choose proper 
clothing for a season or occasion. However, the person usually knows their own name 
and possibly the names of spouse and children. In most cases the individual is still 
toileting and eating independently. 
- Stage six is when there is severe cognitive decline. This stage is included in the 
moderately severe or mid-stage AD categories. During this stage memory declines, 
personality changes may emerge, and extensive assistance is needed with daily activities. 




The symptoms that may be present during this stage include: a loss of awareness of 
recent experiences or activities, impairment in recollection of personal history, occasional 
forgetfulness of spouse and caregiver names, and inability to dress appropriately where 
the person may put pajamas on over clothes or put shoes on the wrong feet. A person in 
this stage of AD may experience other features including a disruption of sleep/wake cycle 
and inability to toilet independently with episodes of incontinence or urine or stool. 
During this stage, significant personality changes may occur. These behavioral symptoms 
may include delusions, hallucinations, and/or repetitive behaviors, as well as wandering 
with increased potential for the individual to get lost.   
- Stage seven is known as the stage with very severe cognitive decline and is categorized in 
the severe or late-stage AD. During this stage the person loses the ability to respond to 
their environment, the ability to speak, and ability to control movement. The individual is 
completely dependent on caregivers for eating and toileting. The individual is unable to 
walk, hold their head up, or sit up without assistance. Reflexes are delayed or absent and 
muscles grow rigid, and there is significant swallowing impairment. 
These stages are summarized in Table 1. 
Table 1: Table of Stages of Alzheimer’s Disease 
Stage Stage title Possible Symptoms/Findings 
Stage 1 No Cognitive Impairment - No memory problems 
Stage 2 Very Mild Decline - Memory lapses 
- Forget familiar words, names, location of keys 
- Problems not evident during a medical examination or the 
friends/family 
Stage 3 Mild Cognitive Decline 
(Early Stage AD) 
- Word or name finding problems noticed by family/friends 
- Decreased ability to remember names when introduced to 
new people 
- Performance issues noticeable to others 
- Retaining little material after reading a passage 
- Misplacing valuable objects 




Stage Stage title Possible Symptoms/Findings 
- Decline in the ability to plan or organize 
Stage 4 Moderate Cognitive Decline 
(Mild or Early Stage AD) 
- Decrease in knowledge of recent events 
- Impaired ability to complete challenging mental arithmetic 
(e.g. count backward from 100 by 7’s) 
- Decrease in capacity to perform complex task (e.g. paying 
bills) 
- A reduction in memory of personal history 
- Subdued or withdrawn  
Stage 5 Moderately Severe 
Cognitive Decline 
(Moderate or Mid-Stage 
AD) 
- Unable to recall address or important details in medical 
interview 
- Confused about date/time/season 
- Trouble with less challenging arithmetic (e.g. count back 
from 20 by 2’s) 
- Assistance needed to choose proper clothing for the season 
or occasion 
Stage 6 Severe Cognitive Decline 
(Moderately Severe or Mid-
Stage AD) 
- Lose awareness of recent experiences 
- Imperfect recollection of personal history 
- Occasionally forget name of spouse or primary caregiver, 
but recognize faces 
- Assistance need to dress properly 
- Disruption of normal sleep/waking cycle 
- Assistance with details of toileting (e.g. flushing toilet) 
- Increase episodes of incontinence 
- Personality/behavioral symptoms, hallucinations, and/or 
compulsive behaviors 
- Wander or get lost 
Stage 7 Very Severe Cognitive 
Decline 
(Severe or Late-Stage AD) 
- Lose capacity for recognizable speech 
- Need assistance with eating and toileting, generally 
incontinent 
- Lose ability to walk without assistance 
- Impaired swallowing 
- Reflexes abnormal and muscles grow rigid 
 
Diagnostics 
 Clinical features for possible AD include: a presentation, or progression of dementia 
without a known etiology, the presence of another potential causative systemic or neurologic 
disorder that is not considered to be the etiology of dementia, and progression of deterioration in 
a single cognitive domain with the absence of any identifiable etiology (Grabowski, 2010). 
 The diagnosis of AD requires a histopathologic examination of the brain (Grabowski, 
2010). Therefore, clinical criteria are used to diagnose AD.  Clinical criteria includes diagnostic 
tests such as laboratory and imaging studies, neuropsychological testing, mental status exam, and 




neurologic exam. Laboratory values, physical exam, and imaging studies are used to exclude 
other diagnoses or etiologies, such as adverse reactions to medications, depression, 
cerebrovascular changes, traumatic brain injury, and/or metabolic deficiencies or disorders. The 
use of neuropsychological testing is helpful in the evaluation of patients with cognitive 
impairment. The neuropsychological testing can differentiate between the diagnosis of dementia 
and depression. A neurophsycological evaluation gives a quantitative measurement of behavioral 
and cognitive abilities of a patient using a variety of clinical tests and exams.  Testing should be 
completed and evaluated by a neuropsychologist to ensure accuracy of results. Testing also 
provides baseline information and is helpful in monitoring the progression of disease.  
Neuropsychological testing is also used to assess and guide recommendations in regards to 
driving, financial decision making compacity, and the need for further supervision/care. A 
complete cognitive and neurologic exam is essential. The Mini-Mental State Examination 
(MMSE) is a widely used quantified screening test for cognitive function to document the 
presence and progression of AD and other dementia diagnoses.  Tombaugh & McIntryre (1992) 
completed a comprehensive review of information collected over a period of 26 years regarding 
the utilization of the MMSE.  Reliability and validity of the MMSE was found satisfactory in 
measuring cognitive impairment (Tombaugh & McIntryne, 1992). The MMSE should not be 
used as diagnostic tool by itself to identify dementia, but it does provide a valid quantitative 
assessment of the severity of cognitive impairment and measurement of cognitive changes over 
time. A score between 20 and 26 on the MMSE indicates early-stage AD (Grabowski, 2010).  
Scores between 10 and 20 are associated with moderate AD.  MMSE score below 10 correlates 
with severe AD.  




According to Grabowski (2010), the National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders 
Association have identified 6 criteria for the diagnosis of AD. These criteria are: 
1.  Clinical examination, standardized brief mental status examination, and 
neuropsychological testing confirms dementia 
2.  Deficits in two or more areas of cognition.  
3.  Progression of worsening memory and cognitive function.  
4.  Normal level of consciousness 
5.  Age of onset is between 40 and 90 years of age 
6.  Absence of other systemic or neurologic disorders sufficient to account for the 
progression of cognitive deficits  
Behavioral Symptoms 
According to Woods, Craven, and Whitney (2005), about 80% of nursing home residents 
with a diagnosis of AD develop behavioral symptoms. Behavioral symptoms of AD can be 
challenging to manage in patients with Alzheimer’s disease. Behavioral symptoms may include 
disruptive vocalization (screaming), restlessness, repetitive questions, wandering, pacing, and 
physical aggression toward self or others. The most frequent reported behaviors include 
disruptive vocalization of approximately 30-48% and restlessness in approximately 29-44% 
(Woods, Craven, & Whitney, 2005).  Behavioral symptoms worsen with progression of the 
disease. This leads to the requirement for higher staff to patient ratios in the nursing 
home/hospital setting.  Behavioral symptoms can lead to a higher risk for falls, which results in 
an associated increased risk of injuries (Hawranik, Johnston, & Deatrich, 2008). Unfortunately, 
the higher staff ratios and costly resultant injuries lead to a rise in overall health care cost. 




 Behavioral symptoms contribute to the use of chemical and physical restraints. As 
defined by Mott, Poole, & Kenrick (2005) a chemical restraint is both the deliberate and 
incidental use of pharmaceuticals to control behavior and/or restrict freedom of movement.  
Haloperidol and benzodiazepine agents, such as lorazepam, are examples of chemical restraints. 
“These drugs may be purposely administered to sedate the patient as a means of convenience” 
(Mott, Poole, & Kenrick, 2005, p. 97).  Most commonly used are short-acting benzodiazepines, 
such as alprazolam and lorazepam (Gutierrez, 2008). Short-acting benzodiazepines enhance the 
effect of the neurotransmitter, gamma-aminobutyric acid (GABA) by binding to the GABA 
receptor sites.  This strengthens the inhibitory effects on neurons in the brain associated with 
anxiety, fear, and arousal resulting in a sedative, hypnotic, anxiolytic, and muscle relaxant effect.  
Adverse effects of benzodiazepines include but are not limited to, dizziness, ataxia, 
restlessness/agitation, and headaches and increase the patient’s risk for falls and decline in 
cognition (Mott, Poole, & Kernick, 2005). Antipsychotic medications, such as haloperidol, are 
used as a chemical restraint.  These medications block dopamine-2 receptors in the mesolimbic 
area of the brain. By blocking the dopamine-2 receptors in the nigrostriatal pathway 
antipsychotic medications can cause extrapyramidal symptoms, including but not limited to, 
dystonia, parkinsonism, and akathisia (Gutierrez, 2008). These medications cause anticholinergic 
effects due to partial blockade of acetycholine. Anticholinergic effects, such as dry mouth and 
eyes, hypotension, and urinary retention are most common. Orthostatic hypotension is an adverse 
effect of antipsychotics increasing the risk for falls. According to Tune (2001) treating AD 
patients with medications with anticholinergic effects can cause vision changes and will likely 
worsen the disease process by causing cognitive decline. Woolcot et al. (2009) completed a 
meta-analysis of 22 articles meeting inclusion criteria on 9 medication classes on falls in the 




elderly.  The 9 medication classes included in the meta-analysis were: sedatives, diuretics, 
antidepressants, benzodiazepines, hypnotics, neuroleptics, narcotics, nonsterioidal anti-
inflammatory drugs, and antihypertensives. Bayesian method of statistical analysis was used for 
medication risk assessment (Woolcot et al, 2009). The meta-analysis concluded the use of 
sedatives, hypnotics, antidepressants, and benzodiazepines significantly increased the risk of 
falls in the elderly population.  
“A physical restraint is any physical or mechanical device, material or equipment 
attached or adjacent to a patient’s body that the individual cannot control or remove easily” 
(Mott, Poole, & Kenrick, 2005, p. 96).  Physical restraints restrict the freedom of movement of 
the patient’s body.  Wrist and ankle restraints, hand mitts, and wheelchair safety bars are 
examples of physical restraints. Physical restraints can cause the patient to become fearful of 
staff and an increase risk of injury occurs. Luo, Lin, & Castle (2011) studied physical restraint 
use in residents of nursing homes with and without dementia, residents with dementia were more 
likely to be physically restrained.  Physical restraints included in this study were trunk (waist) 
restraints, chair restraints, and increased bed rails (Luo, Lin, & Castle, 2011).  The 2004 National 
Nursing Home Survey (NNHS) was the data source for this study.  This is a survey of 
participating nursing homes in the United States. Data was collected for each randomly chosen 
resident.  The final sample for the analysis included 5057 residents with AD or dementia and 
4224 residents without.  A weighted analysis was conducted with the Surveyfreq and 
Surveylogistic procedurs in SAS version 9.1. It was concluded that trunk restraints and chair 
restraints increased the residents risk for falls and injury.  
Caregiver Burden 




Behavioral symptoms seen in an AD patient can lead to caregiver burden issues. 
“Caregiver burden has been defined as a negative reaction to the impact of providing care on 
caregivers’ social, occupational, and personal roles” (Papastavrou, Kalokerinou, Papacostas, 
Tsangari & Sourtzi, 2007, pp. 446). Family caregivers of AD patients have a high incidence of 
depression as consequence of caring for a person with dementia.  A study by Papastavrou, 
Kalokerinou, Papacostas, Tsangari & Sourtzi (2007), found 68.02% of the 172 caregiver sample 
were highly burdened and 65% expressed depressive symptoms. The volunteer sample consisted 
of caregiver/care recipient dyads recruited from neurology clinics in Cyprus from 2004 to 2005. 
The Memory and Behavior Problem Checklist, Burden Interview, Center for Epidemiological 
Studies-Depression Scale and Ways of Coping Questionnaire were utilized by the interviewer for 
data collection. Data was analyzed by using independent samples t-tests, correlation analysis and 
one-way ANOVA followed by post hoc adjustments for multiple comparisons. Germain et al. 
(2009) studied the variables associated with caregiver burden of those caring for AD patients.  
Baseline data was collected from the ICTUS study, which is an ongoing longitudinal prospective 
observational study of AD in Europe from 29 specialist outpatient clinics in 12 countries 
(Germain et al., 2009). A total of 1381 patients and their caregivers were included in the sample 
for analysis. Over a 2 year period, on a 6 month basis, participants were assessed using The 
Burden Interview,  AD Assessment Scale-Cognitive Section (ADAS-Cog), Clinical Dementia 
Rating Scale, Basic Activities of Daily Living, Instrumental Activities of Daily living, and the 
Neuropsychiatric Inventory (NPI). Principal component statistical analysis was conducted with 
Statistica, version 8.0.  1091 caregivers responded to the all of the Burden Interview Items.  34% 
had mild to moderate burden, 9.6% had moderate to severe burden, and 1.4% had severe burden. 
A regression model was used to identify patient characteristics which best predict caregiver 




burden. It was found that behavioral and psychological symptoms including hallucinations, 
delusions, and agitation as one of the most significant contributing variables to caregiver burden. 
 Caregiver burden is a strong determinant of institutionalization of individuals with 
dementia (Papastavrou, Kalokerinou, Papacostas, Tsangari & Sourtzi, 2007). According to 
Gilley, McCann, Benias, & Evans (2005), several dementia cohort studies have found that 
caregiver burden resulting from caring for people with AD increases the risk of 
institutionalization. Institutionalization accounts for the majority of the cost of medical care of 
patients with AD (Gilley, McCann, Benias, & Evans, 2005). Caregiver burden affects the quality 
of life of the caregiver and AD patient negatively (Papastavrou, Kalokerinou, Papacostas, 
Tsangari & Sourtzi, 2007). 
 Although there have been several studies of caregiver burden of family members of 
people with AD, there is minimal research about burden as it pertains to professional caregivers, 
such as long-term care providers (McCarty & Drebring, 2003).  More than 2 million long-term 
care residents have AD type dementia or other conditions causing dementia.  There are 600,000 
to 1.4 million professional caregivers who provide this long-term care. McCarty & Drebring 
(2003) conducted a qualitative, explorative, and descriptive design study to explore and describe 
professional caregivers’ perceptions and meanings associated with caring for residents with AD.  
A sample of 22 caregivers were interviewed. The sample consisted of 1 physician, 6 registered 
nurses, 2 licensed practical nurses, 2 social workers, 1 psychologist, and 10 nursing assistants 
from several long term care environments in Southern New England area. Interview data was 
analyzed with content analysis. The major theme derived from the data was balancing self-care 
with care for patient with AD.  An exclusive pattern associated with this theme was managing 
the patients’ problematic behaviors. “Staff often noted the inevitable death outcome; the long, 




slow process of multiple losses; and the physically and emotionally draining nature of the 
caregiving process” (McCarty & Drebing, 2005, p. 46). Even with limited research there is 
evidence that caregiver burden experienced by paid professional caregivers does exist and needs 
further attention.  
Therapeutic Touch 
 Therapeutic touch is a non-pharmacologic intervention that has been minimally utilized 
for the treatment of behaviors seen in patients with AD. 
Definition 
 There are several related terms associated with therapeutic touch, such as Reiki therapy 
and healing touch. For the purpose of this paper the definition for therapeutic touch, defined by 
Delores Kreiger and stated by Woods, Craven, & Whitney (2005) as: 
Therapeutic touch is an intentionally directed process during which the practitioner uses 
the hands as a focus to facilitate the healing process. As a contemporary interpretation of 
several ancient healing practices, therapeutic touch is founded on the premise that the 
human body, mind, emotions, and intuition form a complex, dynamic field. In health, the 
field is balanced; in disease, the field becomes unbalanced and disordered. (p. 67)  
Therapeutic Touch Practitioners 
 In 2006 it was estimated there were 40,000 practitioners worldwide (Doherty, Wright, 
Aveyard, & Sykes, 2006). There are three levels of certification for practitioners of therapeutic 
touch. These levels are basic, intermediate, or advanced levels (Hawranik, Johnston, & Deatrich, 
2008). Basic level practioners have completed a minimum of 12 contact hours at a basic level 




workshop taught by a qualified therapeutic touch teacher. At the basic level the practitioner can 
perform therapeutic touch, but are required to complete one year of practice with a mentor.  To 
maintain basic level certification it is required to do one of the following: maintain regular 
contact with mentor, practice therapeutic touch at least twice a week with journaling, or biannual 
knowledge skills update with a qualified therapeutic touch teacher (Nurse Healers-Professional 
Associates International, 2010a).  Intermediate level practitioners must complete 14 contact 
hours at the intermediate level of education.  After this completion at the intermediate level they 
can practice independently without a mentor and have the option to complete an application to 
become recognized as a Qualified Therapeutic Touch Practitioner (QTTP).  Practitioners at the 
advanced level are QTTPs who are maintaining practice, have completed further continuing 
education, and are mentors/teachers for therapeutic touch.  Therapeutic Touch and Healing 
certification and credentialing programs require a minimum of 100 hours of education, including 
seminars, workshops, supervised practice, written exams, and skills testing (Hawranik, Johnston, 
& Deatrich, 2008). Students study the energy system of the body, meditation, the therapeutic 
touch procedure, energy techniques for the chakra system, known as the energy center, and the 
spine. The practitioners also study, specific techniques for working with individuals with lung 
disease and cancer. After certification it is expected the practitioner practices therapeutic touch 
on a consistent basis with an average of at least two sessions per week (Nurse Healers-
Professional Associates International, 2010a).  Currently there is not a specified number of 
continuing education hours or renewal process. The standards and scope of practice established 
by the Nurse Healers-Professional Associates International (2010a) state that practitioners are 
expected to have consistent practice, continuing education, and mentoring. According to the 
Nurse Healers-Professional Associates International (2010a), anyone can become certified as a 




therapeutic touch practitioner.  However, licensed health care professionals, such as nurses, who 
become certified, can practice in hospitals and other health care settings within the individual 
policies of the institution. Practitioners who are not health care professionals must practice 
according to each individuals state regulations of where they can practice therapeutic touch. All 
therapeutic touch practitioners are responsible to practice according to state law and regulations.  
Process of Therapeutic Touch 
 There is a process of therapeutic touch utilized to identify and correct energy imbalances 
(Hawranik, Johnston, & Deatrich, 2008). During a therapeutic touch treatment the individual is 
generally not physically touched.  The process of therapeutic touch is included in the therapeutic 
touch policy and procedure for health care professionals (Healers-Professional Associates 
International, 2010b). Therapeutic touch begins with an explanation of the procedure and verbal 
permission is obtained whenever possible. The practitioner explains therapeutic touch as a 
relaxation intervention to relieve pain, decrease anxiety, and/or promote a sense of well being. 
The practitioner brings the person’s body, mind, and emotions to a quiet, focused state of 
consciousness. This is to be maintained throughout the session. A baseline energy pattern 
assessment is completed by assessing the energy field. The practitioner becomes aware of 
differences in the energy field with sensory cues in the palmar surfaces of their hands by holding 
hands about 2-4 inches away from the individual’s body in a head to toe direction. Calm and 
rhythmic hand movements are used to clear areas of energy imbalance. This assessment and 
rhythmic hand movements are continued throughout treatment to determine when the session is 
completed. Once treatment is completed the individual is given an opportunity to rest and the 
response is evaluated by the practitioner. Outcomes of the session are then documented by the 
practitioner, followed by development of an intervention plan. Therefore, the time needed for the 




intervention and the number of sessions is determined by the practitioner. In general, the actual 
intervention time is 15-25 minutes per session. The practitioner is expected to view the client 
from perspective of wholeness so the client is seen as an open, complex, and pandimensional 
energy system. The client perceptions are acknowledged, valued, and respected in a non-
judgmental manner by the practitioner. The practitioner collaborates with the health care team of 
the client.  
Effects of Therapeutic Touch 
 The effects of therapeutic touch include a variety of clinical situations. The most 
consistent result of therapeutic touch is a relaxation response (Woods & Dimond, 2002). This 
response decreases the physiological response to stress by activating the parasympathetic 
nervous system. Therefore, therapeutic touch can be used to reduce anxiety and stress, relieve 
pain, improvement of immune system function, lower blood pressure, and improve wound 
healing (Hawranik et al, 2008).  When the therapeutic touch process is completed on individuals 
with AD exhibiting behavioral symptoms it is expected that the relaxation response will decrease 
the amount and intensity of the behavioral symptoms.  
Literature Review 
The research on the use of therapeutic touch to treat agitation in AD is limited.  Several 
studies support that therapeutic touch and closely related therapies such as, healing touch, and 
Reiki therapy are beneficial in treating agitation in dementia patients.  
 Wang & Hermann (2006) conducted a pilot study to test the effectiveness of healing 
touch on agitated people diagnosed with dementia. The study was a nonrandomized quasi-
experimental study to assess the effectiveness of healing touch in lowering agitation levels of 




residents with dementia.  The study took place in an 18 bed dementia special care unit in Prescott, 
Arizona. The agitation levels of residents were measured using the Cohen-Mansfied Agitation 
Inventory (CMAI).  The CMAI measures agitation based on a compilation of observable 
behaviors. Agitation levels are then rated by calculating the frequency of the 29 behaviors. There 
was a sample size of 14 male residents included in the study.  14 was the census of the special 
care unit during the time of this study and were all included in the study.  CMAI scores were 
recorded for two weeks to determine the control and treatment group. The control group included 
the residents who had lower CMAI scores.  The treatment group included the residents who 
achieved higher CMAI scores.  Eight were in the control group and six were in the interventional 
group receiving healing touch therapy for 10 minutes a day for four weeks. A mean agitation 
level was assessed and reported from the group as a whole prior to receiving the intervention.  
During the treatment period the intervention group had a significant decrease in agitation as 
compared to the control group. The statistical hypothesis test was used to test the significance of 
the results. It was concluded that the treatment group response has lower agitation levels than the 
non-treatment group, with a ± = 0.05 level.  Qualitative observations of patient behavior were 
done using a separate data sheet. Included in this collection were observations of participant 
behavior and comments. According to these qualitative observations several participants often 
stated they felt relaxed after treatment and they enjoyed it. Three of the residents receiving 
psychotropic meds in the treatment group had a decrease in their prescribed dosages during and 
after the treatment. It was also reported that two of the residents in the treatment group had a 
dose increase 2 weeks after treatment was stopped.  Although the sample size was small and the 
study was nonrandomized, healing touch treatment was found to be an effective intervention for 
the treatment of agitation. No negative effects of the treatment were identified or reported. 




A study by Skovdahl, Sorlie, & Kihlgren (2007) examined the effect of tactile stimulation 
treatments on the occurrence of aggressive behaviors. A method of tactile massage was 
developed in Sweden in the 1990s.  It is a form of soft strokes reaching only the tactile receptors, 
rather than deep tissues. The aim of tactile stimulation is to convey attention and promote well-
being to decrease worry and stress. A sample of 40 trained caregivers were instructed to provide 
tactile stimulation at a minimum of once per week, with a goal of daily over a 28 week period. 
The tactile stimulation was provided to twenty residents from 4 different wards of a nursing 
home. Residents who received the tactile stimulation therapy had a diagnosis of moderate to 
severe dementia and exhibited restlessness and aggressive behaviors.  Documentation of the 
intervention was done on a form developed by the authors. Included on the documentation form 
was: the week of the study, the date of treatment, duration of treatment time, person who 
provided the treatment, where the treatment took place, and the parts of the body being 
stimulated.  The provider of the treatment gave their description of the session by answering 5 
questions.  There was an area for comments, but none of the providers made further comments. 
Findings from the study were summarized and reported using a random sample of 5 of the 
residents included in the study. All residents displayed signs of positive feelings and relaxation 
during and after tactile stimulation. The caregiver’s reported positive interactions with the 
residents which lead to a warmer relationship. Overall, it was found tactile stimulation was 
beneficial technique to promote relaxation and better therapeutic connections with residents.   
 Developments in neuroendocrinology suggest there is an alteration of the hypothalamic-
pituitary-adrenal axis as AD progresses resulting in an increase of salivary and urine cortisol 
levels (Woods & Dimond, 2002).  A study conducted by Woods & Dimond (2002), studied the 
effect of therapeutic touch on agitated behavior and cortisol levels of persons with AD.  A 




sample of 10 residents of a special care unit participated in this pilot study. The residents 
exhibited moderate to severe agitation behavior with a score of 15 or higher on the Brief 
Agitation Rating Scale (BARS).  The BARS is a shorter version of the CMAI used to measure 
agitation.  A score of 15 or higher signified high agitation. Baseline agitation levels for each 
participant were collected for 4 days prior to the intervention. Therapeutic touch was performed 
for 5 to 7 minutes twice a day for 3 days. Post-treatment data was collected for 9 days. During 
data collection for baseline, treatment and pos-treatment, urine and salivary samples were 
collected to analysis the cortisol levels. A modified Agitated Behavior Rating Scale was used by 
observers to measure the dependent variable, frequency, and intensity of agitated behavior. The 
five major behaviors measured on this scale included manual manipulation, escape from 
restraints, searching or wandering, tapping or banging, and vocalizations. Freidman rank scores 
and analysis of variance (ANOVA) were calculated to assess a change over time in the outcome 
measures. These scores showed a decrease in agitated behaviors overall, with the most prominent 
decrease during the treatment periods.  ANOVA indicated a significant decrease in agitated 
behavior, specifically vocalization and pacing or walking during treatment and post-treatment. 
There was no significant decrease trend in saliva or urine cortisol levels according to ANOVA 
and the Friedman rank test. However, there was a decrease trend in urine and cortisol levels 
reported from treatment to first post-treatment period suggesting a treatment effect.  Due to the 
small sample size the statistical power of cortisol levels is limited and the lack of a comparison 
group limited definitive conclusions. Woods & Dimond (2002) concluded therapeutic touch has 
the potential to decrease the most prevalent behaviors, vocalization and pacing, and suggests 
further research and larger samples to examine the effect of therapeutic touch on agitated 
behaviors and cortisol levels.  




 Woods, Craven, & Whitney (2005) studied the effect of therapeutic touch on the 
frequency and intensity of behavioral symptoms of dementia. A randomized, double-blind, three-
group experimental study was conducted using 57 residents aged 67-93 years old. The three 
groups of the study were placebo, experimental, and control. The residents included in the study 
exhibited behavioral symptoms associated with dementia. Residents were randomized into 
groups from three special care units within three long term care facilities in a western Canadian 
province. Therapeutic touch was given to the experimental group for 5-7 minutes twice daily for 
3 days. Trained observers recorded behavioral observations every 20 minutes for 3 days pre-
intervention, 3 days of treatment, and 3 days post treatment of all three groups. Observers were 
blind to group assignments. A significant difference in behavioral symptoms was found in the 
experimental group according to the ANOVA and Kruskal-Wallis test.  In conclusion the study 
supports that therapeutic touch has clinical relevance to decrease behavioral symptoms in 
patients with dementia. 
 A study was reviewed regarding the effectiveness of therapeutic touch and agitation in 
individuals diagnosed with AD by Hawranik, Johnston, & Deatrich (2008). This was a 
randomized, multiple time series, three-group experimental design.  The design was used to 
study the difference in effect of therapeutic touch on agitation of older residents with AD 
compared to those who received a simulated therapeutic touch and another group who received 
usual care. The multiple time series design measured agitation levels using the CMAI 2 hours 
after each treatment, 24 hours after final treatment, 1 week after final treatment, and 2 weeks 
after the final treatment. The sample used in the study included 51 residents diagnosed with AD 
of a long term care facility. There were 16-18 residents per group.  One group received 
therapeutic touch once per day for 5 days, the second group received simulated therapeutic touch 




once per day for 5 days, and the other group received their usual care.  Generalized estimated 
equations for analysis of repeated measures of discrete outcomes were utilized in the 
multivariable analysis. The effects of treatment were reported as incidence ratios with 95% 
confidence intervals. Physical non-aggressive behaviors decreased significantly in residents of 
the therapeutic touch group. The study provided preliminary evidence for the potential of 
therapeutic touch as an effective treatment in decreasing non-physical aggressive behaviors such 
as wandering and restlessness.  
 Wardell & Weymouth (2004) conducted a systematic review of studies of healing touch 
and its implications for practice and research. Over 30 studies were analyzed and reviewed. The 
studies were divided into eight categories according to the target of the intervention and the 
outcomes evaluated. Categories included pain, cancer, immune, cardiovascular, elderly, mental 
health, postoperative recovery, theoretical, and pediatrics. Included in the elderly category were 
two studies conducted by Ostuni & Puietro in 2001 finding an overall improvement of behavioral 
symptoms in patients with AD related to healing touch treatments. A study by Wang & Hermann 
in 1999 found a decrease in agitation levels in dementia patients who received health touch. The 
overall data reviewed in the elderly category supports the use of healing touch for the elderly 
population to decrease behavioral symptoms.  
 Appendix A summarizes the studies in this literature review. 
Recommendations 
  Health care providers are challenged with the management of patients with AD 
exhibiting aggressive and agitated behaviors.  Caregivers of AD patients exhibiting these 
symptoms can become burdened and stressed. An intensive review of the literature and studies 




on the use of therapeutic touch as an intervention to treat behavioral symptoms of AD indicates 
that it is appropriate for primary care givers to consider therapeutic touch therapy to treat 
behaviors of patients with AD. It has been found through research to decrease stress and anxiety, 
and to improve quality of life and emotional, physical, and spiritual well-being. Despite a limited 
amount of available research, collectively the evidence have shown therapeutic touch does not 
cause patients any harm. There is an improvement of agitation and other behavioral symptoms 
with the use of therapeutic touch.  The comprehensive literature suggests considering therapeutic 
touch as an intervention to treat agitated behaviors of clients with AD.  Therapeutic touch 
decreases agitation making it easier to provide care to AD patients, which relieves caregiver 
burden.  In order for caregiver’s to provide quality care for patients with AD, there is a need for 
decreased stress. Therefore, therapeutic touch therapy can improve the quality of life of the 
patient with AD and their caregiver’s. 
Implications for Practice 
 It is important for primary care providers to consult with a certified therapeutic touch 
practitioner when suggesting therapeutic touch therapy.  The consultation should include a 
discussion of the patient’s medical history and behavioral symptoms. Once it has been decided 
by the primary care provider, the patient’s guardian/caregiver, and the therapeutic touch 
practitioner to provide therapeutic touch therapy, the practitioner will complete an assessment 
and treatment plan.  The therapies will be given by the practitioner according to the treatment 
plan and evaluated.  If the patient and caregiver are satisfied with the treatment and outcomes, 
the practitioner can continue treatments according to his/her guidelines. The primary care 
provider is responsible to continue monitoring behavioral symptoms and treat as necessary in 
conjunction with the therapeutic touch therapy.  




 Considering cost containment, therapeutic touch is a non-invasive, readily learned, non-
pharmacologic intervention to treat selected behavioral symptoms (Woods, Craven & Whitney, 
2005).   Therapeutic touch is low in cost and can be applied and practiced in many settings 
without specialized equipment. Most often therapeutic touch practitioners are supported by 
donations or the organization (hospital or nursing home) itself (Bach, 2011). Some therapeutic 
touch practitioners volunteer their services to organizations. Therefore, it is probable that AD 
patients who are living in a nursing home setting have access to therapeutic touch practitioners 
covered by the organization. According to the National Center for Complementary and 
Alternative Medicine (NCCAM) (2010a), touch therapies are classified as an energy field 
practice, which is recognized as a complementary and alternative medicine (CAM) practice.  
Coverage of CAM by insurance companies is relatively limited compared to coverage of 
conventional therapies (NCCAM, 2010b). Medicare does not cover therapeutic touch therapy. 
However, if the rise in utilization of CAM continues, it is expected insurance companies will 
consider covering CAM found to be safe and effective.  The average cost is $40-$90 per hour 
with a therapeutic touch practitioner (Bach, 2011). Regardless of the cost of therapeutic touch 
treatment outside of a nursing home or hospital setting it is less than the cost of 
institutionalization of the individual. Therefore, therapeutic touch is a cost-effective and non-
invasive intervention to consider when treating behavioral symptoms of AD. See Diagram 1. 
Diagram 1:  Treating Behavioral Symptoms 





Education and Counseling 
 Patients with AD and their caregivers need to understand that therapeutic touch is used to 
treat a symptom associated with AD.  Therapeutic touch is not a treatment intended to slow the 
progression or cure AD.  Providers of therapeutic touch are responsible for educating the family 
and patients about the goals of therapeutic touch treatment and the expected results of treatment.  
Therapeutic touch may or may not be appropriate for all behavioral symptoms depending on the 
individual’s response to treatment, making it crucial for collaboration of the practitioner and 
primary provider. The overall goal of using therapeutic touch as an intervention to treat 
behavioral symptoms of AD is to improve the quality of life of the patient with AD and their 
caregivers/family. 
 The process of therapeutic touch needs to be explained to the patient and their caregivers. 
If the patient is confused the practitioner is expected to attempt to explain the process to the 
patient.  If the confused patient refuses treatment the practitioner will offer treatment at a 
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different time and discuss the patient’s refusal for treatment with the caregiver. Therapeutic 
touch is most effective if the patient receives sessions on a consistent basis established by the 
practitioner, therefore the caregiver should be encouraged to stay on track with therapeutic touch 
therapy sessions. It is important to reassure the patient and caregiver that therapeutic touch does 
not cause any harm to the person receiving treatment. If the patient is non-compliant with 
treatment the practitioner will not force the client to participate and will adjust the treatment plan 
accordingly. With this explanation it is important to indicate that some patients may not respond 
to treatment, if so, the caregivers, family, and primary care provider will explore alternate 
treatments together. 
If caregiver stress and burden are suspected, the provider should provide the caregiver 
with resources and education regarding behavioral symptoms. Included in this education should 
be the expected stages of AD, and preparing families/caregivers for the progression of the 
disease. Resources, such as respite care or supplemental caregivers should be offered and 
discussed. Give them encouragement to contact their primary care provider for support or any 
questions they may have.  
 Education and counseling for patients with AD and their families/caregivers is ongoing 
and needs to be addressed at a minimal of each provider appointment.  
Conclusion 
 AD is a progressive disease effecting millions of people across the world. AD can cause 
challenging behavioral symptoms for the patient, family, and/or caregiver. Advances in the care 
for the AD population have led to use of therapeutic touch as an intervention to treat agitated 
behaviors. Although research is limited, the common result is that therapeutic touch can decrease 




agitated behaviors, improving the quality of life the person with AD and their caregivers. 
Collaboration of primary care providers, families and caregivers of patients with AD, and 
therapeutic touch practitioners is crucial for therapeutic touch to be effective. Education and 
counseling regarding AD and the goals of therapeutic touch therapy need to be addressed prior to 
treatment and should continue throughout the treatment plan. Therapeutic touch is a cost-
effective, non-invasive intervention for primary care providers to consider when treating AD 
patients with agitated behaviors. 
Recommended Internet Sites 
 The Alzheimer’s Association website (www.alz.org) provides information on AD for 
patients, families, caregivers, and health care professionals. The website is user friendly and 
provides updated information on current and completed research on AD. 
 The Nurse Healers- Professional Associates International has provided a website 
(www.therapeutic-touch.org) with information on therapeutic touch. The scope of practice of 
therapeutic touch, credentials and training for practitioners of therapeutic touch, and history can 
be found on this website. A database of certified therapeutic touch practitioners is available. It is 
a reliable website when researching the process and goals of therapeutic touch for health care 
professionals and others interested in therapeutic touch. 
 The Center for Disease Control website (www.cdc.gov) is a helpful website to find facts, 
general information, current research, and statistics regarding a wide range of diseases and 
illnesses.  The website can be challenging to navigate, but the information provided is valuable 
to health care professionals and the general public. 




 The United States Department of Health and Human Services provides a website from 
the National Institutes of Health (www.nih.gov).  This website provides information about health, 
disease, research, and guidelines. The website has numerous links to resources making the 
website difficult to find what you are interested in. However the information provided is reliable 


























Appendix A: Table of Studies of Literature Review 
Title Author/Year Description Results 








Wang & Hermann 
(2006) 
Nonrandomized quasi-experimental 
study to assess the effectiveness of 
healing touch in lowering agitation 
levels of residents with dementia;    
sample size of 14 male residents (8 in 
control group; 6 in the interventional 
group); healing touch therapy for 10 
minutes a day for four weeks.  A 
mean agitation level was assessed 
and reported from the group as a 
whole prior to receiving the 
intervention.   
Significant decrease in agitation in 
interventional during treatment: 
treatment response is lower in 
agitation than the non-treatment 
response at the ± = 0.05 level; 
participants stated how they felt 
relaxed after treatment and enjoyed 
it.  Three of the residents receiving 
psychotropic meds in the treatment 
group had a decrease in their 
prescribed dosages during and after 
the treatment. It was also reported 
that two of the residents had a dose 
increase 2 weeks after treatment was 

















& Kihlgren (2007) 
Over 28 weeks, a 40 trained 
caregivers were instructed to provide 
tactile stimulation at a minimum of 
once per week, with the optimum 
goal of daily. Twenty residents from 
4 different wards of a nursing home, 
with a diagnosis of moderate to 
severe dementia exhibiting 
restlessness and aggressive 
behaviors, received the tactile 
stimulation intervention.  
 All residents displayed signs of 
positive feelings and relaxation 
during and after tactile stimulation. 
The caregiver’s felt they had 
interacted with the residents in a 
more positive way leading to a 
warmer relationship with the 
residents. Overall, it was found 
tactile stimulation is a beneficial 
technique to promote relaxation and 
better therapeutic connections with 
residents.   









Woods & Dimond 
(2002) 
Pilot study: sample of 10 residents 
from a special care unit with 
moderate to severe agitated behavior 
and a score of 15 or higher on the 
Brief Agitation Rating Scale. A 
practitioner performed therapeutic 
touch for 5 to 7 minutes twice a day 
for 3 days. For nine days post-
treatment data collection continued.  
Throughout the study, urine and 
salivary samples were collected to 
analysis the cortisol levels. A 
modified Agitated Behavior Rating 
Scale was used by observers to 
measure the dependent variable, 
frequency, and intensity of agitated 
behavior.  
The study resulted in no decrease in 
each category of behavior, however 
Freidman rank scores showed a 
decrease in agitated behaviors 
overall, with the most prominent 
decrease during the treatment 
periods. There was a decreasing 
trend in saliva or urine cortisol 
levels reported. The Study 
concluded therapeutic touch has the 
potential to decrease the most 
prevalent behaviors, vocalization 
and pacing, and suggests further 
research and larger samples to 
examine the effect of therapeutic 
touch on agitated behaviors and 
cortisol levels.  
 





Woods, Craven & 
Whitney (2005) 
Randomized, double-blind, three-
group experimental study; 57 
residents aged 67-93 years old 
exhibiting behavioral symptoms 
associated with dementia. The three 
A significant difference in 
behavioral symptoms was found in 
the experimental group according to 
the analysis of variance and 
Kruskal-Wallis test.  In conclusion 




Title Author/Year Description Results 
persons with 
dementia 
groups of the study were placebo, 
experimental, and control. Residents 
were randomized into groups from 
three special care units within three 
long term care facilities; Therapeutic 
touch was given to the experimental 
group for 5-7 minutes twice daily for 
3 days. Trained observers recorded 
behavioral observations every 20 
minutes for 3 days pre-intervention, 3 
days of treatment, and 3 days post 
treatment of all three groups. 
Observers were blind to group 
assignments.  
the study supports that therapeutic 
touch has clinical relevance to 
decrease behavioral symptoms in 












Randomized, multiple time series, 
three-group experimental design; 
Sample of 51 residents diagnosed 
with AD from  a long term care 
facility; 16-18 residents per group;  
One group received therapeutic touch 
once per day for 5 days, the second 
group received simulated therapeutic 
touch once per day for 5 days, and 
the other group received their usual 
care.  Agitation levels were measured 
at various times after the treatment 
and compared.   
The study concluded therapeutic 
touch was effective in decreasing 
non-physical aggressive behaviors 
such as wandering and restlessness, 
but did not reduce physically 







Review of studies of healing touch 
and its implications for practice and 
research. Over 30 studies were 
analyzed and reviewed. The studies 
were divided into eight categories 
according to the target of the 
intervention and the outcomes 
evaluated.  
The overall data reviewed in the 
elderly category supports to use of 
health touch for the elderly 
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